Pulmotect

Executive Summary

Pulmotect is a clinical-stage biotechnology company pioneering a novel approach to respiratory infection prophylaxis and treatment. Its lead asset, PUL-042, is an inhaled small-molecule therapeutic designed to activate the innate immune system in the lungs, providing rapid and broad-spectrum protection against viral, bacterial, and fungal pathogens. Unlike vaccines or antivirals, PUL-042 triggers a non-specific immune response, potentially offering immediate protection within hours and efficacy against emerging or drug-resistant strains. The company has completed Phase 1 safety trials and is advancing PUL-042 into Phase 2 studies for the prevention of respiratory infections in high-risk populations, such as immunocompromised patients. Its unique mechanism of action and inhaled delivery route position it as a potential first-in-class therapy with significant commercial and public health potential.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 clinical data readout for PUL-042 in prevention of respiratory infections40% success
• Q3 2026New partnership or licensing deal for PUL-042 in specific patient populations30% success
• Q4 2026FDA feedback or designation (e.g., Fast Track, Breakthrough Therapy) for PUL-04235% success